A non-interventional post-authorisation safety study to investigate the risk of mortality in multiple sclerosis patients treated with alemtuzumab (LEMTRADA®) relative to comparable multiple sclerosis patients using other disease modifying therapies: a cohort study

26/08/2021
23/10/2025
EU PAS number:
EUPAS42543
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

alemtuzumab-lemtrada-pass-mort-protocol-may-2021_Redacted

English (2.09 MB - PDF) View document
Updated protocol

Redacted_ lem-mortality[csa002]-protocol-amendment-v4.0.pdf

First published: 25/02/2025
English (2.02 MB - PDF) View document
Study results
Study results

alemtuzumab_mort_csa0002_abstract_upload_emahma_22april2025.pdf

English (198.38 KB - PDF) View document
Study report
Other information
Study, other information

lem_pass_mort_protocol_may192021

English (1.37 MB - PDF) View document